Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday November 17, 2009

DrStockPick.com Stock Report!

PWRM, NGSX

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday November 17, 2009 are:

**************************************************************

NGSX, NeurogesX, Inc.

NGSX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies.

** The U.S. Food and Drug Administration (FDA) has approved NGSX’s Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia, the nerve pain which can follow an attack of shingles.

NGSX’s Qutenza delivers a synthetic form of capsaicin, the substance in chili peppers that gives them their heat sensation, through a dermal delivery system, providing up to 12 weeks of reduced

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday September 25, 2009

DrStockPick.com Stock Report!

PWRM, PFE, NVS

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II

...

On Friday, Avigen Inc. (AVGN) announced that it will be purchased by MediciNova, Inc. (MNOV) for $1.24 per share in either cash or secured convertible notes. The deal has been valued at about $37 million. Approximately $1.19 of the consideration is scheduled be paid to Avigen shareholders upon the closing of the deal. The remaining 5 cents will be paid on June 30, 2010, subject to certain adjustments. Additionally, they will be entitled to a contingent payment right which will enable them to receive certain other payments. The deal is expected to close in the fourth quarter of this year, subject to shareholders' approval. Avigen has been on the lookout for a buyer ever since its lead candidate AV650 -- for the treatment of spasticity associated with multiple sclerosis (MS) -- failed in a mid-stage trial last October. The merger will permit the companies ...

On June 29, Sangamo BioSciences Inc. (SGMO) said it will receive a milestone payment from Genentech Inc., now wholly owned by Swiss drugmaker Roche, for a key research milestone achieved under the Research and License Agreement. However, the amount of the milestone payment was not disclosed.

As a reminder, Sangamo and Genentech entered into a Research and License Agreement in late April 2007 and expanded the agreement in February 2008. Under the deal, Sangamo will provide Genentech access to its proprietary zinc finger DNA-binding protein (ZFP) technology and will design and engineer ZFP nucleus (ZFN(TM)) for Genentech to evaluate and potentially use for generation of cell lines with novel characteristics for protein pharmaceutical production purposes.

We feel that the ZFP technology provides a platform for diverse drug research and development at the DNA level. ZFP technology is unique and differentiated from other technologies. ZFP can target any

...

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.  

Genzyme [GENZ: 58.37, -0.29 (-0.49%)]: On 5/21/09, GENZ announced that it has submitted the final documentation to address all items in the FDA’s complete response letter from 3/2/09 (CRL) for Lumizyme (alglucosidase alfa), which is produced at the 2,000 L bioreactor

...

Below are 12 extreme FDA trades for 11 companies with market caps below $200M which have pending new drug product decisions or other meetings/milestones scheduled with the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in extreme FDA and Clinical Trial Calendar trades, which are highlighted in periodic articles at BioMedReports.com.

Hemispherx Biopharma [HEB: 1.36, -0.10 (-6.85%)]: Ampligen (Poly I: Poly C12U) NDA (three month PDUFA decision date delay was announced on 2/18/09 as additional data was submitted by HEB within three months of original decision date). Ampligen is an experimental treatment for chronic fatigue syndrome (which has no

...

Abbott Labs Still Expects TriLipix Approval in 4Q08 Despite an unknown delay from the FDA on TriLipix, Abbott Labs (ABT) still expects approval before year-end. Other updates include a three month delay for Hologic (HOLX) and KV Pharma (KV-A) for Gestiva and a NDA filing yesterday for NeurogesX (NGSX) for its capsaicin skin patch (NGX-4010) in the treatment of post-herpetic neuralgia (nerve pain following shingles infection).